Four months after Immune Design halted a late-stage study for its lead cancer vaccine and saw its stock price cut nearly in half, the immunotherapy company is now in line to join […]
Johnson & Johnson has joined AbbVie as a partner for Morphic Therapeutic and its small-molecule integrin platform, pledging up to $725 million to the cause. https://www.fiercebiotech.com/biotech/morphic-bags-j-j-as-second-big-pharma-partner-for-oral-integrins?utm_source=internal&utm_medium=rss
AbbVie, a research-based global biopharmaceutical company and Eisai Co., Ltd. announced that they have received approval for an https://www.technology.org/2019/02/21/abbvie-and-eisai-announce-fully-human-anti-tnf-alpha-monoclonal-antibody-humira-is-the-first-in-japan-to-be-approved-for-the-treatment-of-hidradenitis-suppurativa/
A new observation highlights the importance of previously unstudied mutations that arises early in bnAbs, giving the antibodies the flexibility to adapt to changes in the virus’s outer envelope protein structure. This […]
Credit: Henry et al./Cell Host & Microbe The influenza vaccine may be less effective in the elderly because their B cells are less capable of producing antibodies that can adapt to protect […]
Discovery may also help scientists develop childbed fever vaccine Credit: NIH National Institute of Allergy and Infectious Diseases (NIAID) HOUSTON-(Feb. 18, 2019) – Houston Methodist infectious disease scientists have discovered a previously […]
Credit: Antonio Peixoto, Claude Gutierrez, and Olivier Neyrolles | IPBS | CNRS/UPS The bacteria responsible for tuberculosis can be killed by a toxin they produce unless it is neutralized by an antidote […]
Credit: EMBL Hamburg Tuberculosis (TB) is one of the top ten causes of death worldwide. In 2017, 10 million people around the world fell ill with TB and 1.3 million died. The […]
A European academic research collaboration has found a new potential weapon against antibiotic-resistant tuberculosis: its own toxins. Many types of bacteria, such as the pathogen responsible for the deadly lung disease tuberculosis, […]
In 1983, the United States Congress passed the Orphan Drugs Act designed to encourage the development of drugs for rare orphan diseases. The EU followed suit in early 2000 as well as […]
